CTOs on the Move

Ralph Lauren

www.ralphlauren.com

 
Ralph Lauren Corporation is a global leader in the design, marketing, and distribution of luxury lifestyle products. Founded in 1967, the company has established itself as a prominent American lifestyle brand, recognized for its iconic designs and contributions to fashion. Ralph Lauren offers a diverse range of products, including apparel for men, women, and children, as well as footwear, accessories, home furnishings, fragrances, and luxury hospitality ventures. The brand portfolio features well-known lines such as Ralph Lauren, Polo Ralph Lauren, and Lauren Ralph Lauren, among others. The company employs a multichannel distribution strategy, utilizing retail stores, online platforms, and licensing partnerships to ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Wood Banani Bouthillette Parizeau

Wood Banani Bouthillette Parizeau Inc. is a Nepean, ON-based company in the Business Services sector.

Graphx

Graphx is a Woburn, MA-based company in the Business Services sector.

International Center for Entrepreneurial Development

International Center for Entrepreneurial Development is a Cypress, TX-based company in the Business Services sector.

The Rescue Mission

The Rescue Mission, founded in 1903, is a faith-based, nonprofit, 501(c)(3) organization, providing restorative care to men, women and children experiencing a homeless crisis. Our organization serves Fort Wayne, Allen County and its nine surrounding co...

Skye Bioscience Inc.

Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.